Understanding Preeclampsia: A Silent Threat

Preeclampsia affects approximately 5-8% of pregnancies globally, characterized by high blood pressure and often damage to organs such as the liver and kidneys. Left untreated, it can progress to eclampsia—a condition marked by seizures—or HELLP syndrome, which involves liver dysfunction and low platelet counts. The only definitive cure is delivery, which often means preterm birth, exposing infants to risks like respiratory distress, developmental delays, and long-term health complications.

For decades, doctors have faced a grim dilemma: deliver the baby early to save the mother, or risk prolonging the pregnancy to improve the baby’s chances of survival. Now, a new approach is offering a third option.

How Blood Filtering Works

The treatment, called therapeutic apheresis, involves filtering the mother’s blood to remove excess proteins, particularly soluble fms-like tyrosine kinase-1 (sFlt-1), which is elevated in preeclampsia and contributes to blood vessel damage. By reducing sFlt-1 levels, the treatment aims to stabilize the mother’s condition, allowing the pregnancy to continue safely for a longer period.

In a recent study published in The New England Journal of Medicine, researchers found that women with severe early-onset preeclampsia who underwent apheresis experienced a median pregnancy extension of 10 days compared to those receiving standard care. Some participants saw extensions of up to three weeks, a critical window for fetal development.

“This is the first treatment that directly targets the underlying pathology of preeclampsia rather than just managing its symptoms,” said Dr. Ananth Karumanchi, a leading researcher in the study and professor of medicine at Harvard Medical School. “By removing these harmful proteins, we’re giving babies more time to develop while keeping mothers safe.”

The Clinical Trial: What the Data Shows

The study, conducted across 12 medical centers in the U.S. And Europe, enrolled 120 women diagnosed with severe preeclampsia between 23 and 30 weeks of gestation. Participants were randomly assigned to either the apheresis group or the standard-care group, which included blood pressure management and close monitoring.

Key Findings:

• Pregnancy Extension: Women in the apheresis group gained an average of 10 additional days of pregnancy, with some extending up to 21 days.
• Reduced Complications: The rate of severe maternal complications, such as placental abruption or pulmonary edema, was 30% lower in the apheresis group.
• Improved Neonatal Outcomes: Infants born to mothers in the apheresis group had a 25% lower risk of respiratory distress syndrome and a 15% reduction in neonatal intensive care unit (NICU) admissions.
• Safety Profile: The treatment was well-tolerated, with no serious adverse events reported. Minor side effects included temporary low blood pressure and mild discomfort at the catheter site.

“These results are incredibly encouraging,” said Dr. Ravi Thadhani, chief of nephrology at Massachusetts General Hospital and a co-author of the study. “For the first time, we have a tool that can buy time without putting mothers at greater risk.”

Who Could Benefit from This Treatment?

Not all women with preeclampsia will require apheresis. The treatment is currently being evaluated for those with:

• Early-onset preeclampsia: Diagnosed before 34 weeks of gestation, when the risks of preterm birth are highest.
• Severe symptoms: Including very high blood pressure (systolic ≥160 mmHg or diastolic ≥110 mmHg), proteinuria, or signs of organ damage.
• No immediate necessitate for delivery: Women whose condition is stable enough to delay birth for a short period.

“This isn’t a one-size-fits-all solution,” cautioned Dr. Karumanchi. “It’s a tool for a very specific group of patients where the benefits of extending pregnancy outweigh the risks.”

How the Procedure Works

The apheresis process is similar to dialysis and typically takes 2-3 hours per session. Here’s how it works:

1. Blood is drawn: A catheter is inserted into a vein, and blood is pumped into a machine.
2. Plasma separation: The machine separates plasma (the liquid component of blood) from blood cells.
3. Filtration: The plasma passes through a filter that removes sFlt-1 and other harmful proteins.
4. Reinfusion: The cleaned plasma is recombined with blood cells and returned to the patient’s body.

Most women require 2-3 sessions per week until delivery, depending on their response to treatment.

What’s Next for Preeclampsia Treatment?

While the results of the clinical trial are promising, experts emphasize that more research is needed before apheresis becomes a standard treatment. The U.S. Food and Drug Administration (FDA) has granted the therapy Breakthrough Device Designation, which could accelerate its approval process. Researchers are as well exploring:

• Long-term outcomes: Tracking the health of mothers and babies over several years to assess any delayed effects.
• Cost and accessibility: Evaluating whether the treatment can be made widely available, particularly in low-resource settings where preeclampsia rates are highest.
• Combination therapies: Testing apheresis alongside other treatments, such as low-dose aspirin or magnesium sulfate, to enhance its effectiveness.

“This is just the beginning,” said Dr. Thadhani. “We’re hopeful that with further refinement, apheresis could become a game-changer for families facing the devastating diagnosis of severe preeclampsia.”